PLK4-IN-7
PLK4-IN-7 is a selective and orally active PLK4 inhibitor with an IC50 value of 7.9 nM. PLK4-IN-7 exhibits potent antitumor activity and favorable metabolic stability. PLK4-IN-7 can be used for the research of tumors such as neuroblastoma.
For research use only. We do not sell to patients.
- Formula: C20H19F6N7O2
- Molecular Weight:503.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
PLK4 7.9 nM (IC50) |
In Vitro
PLK4-IN-7 (Compound 25) (5 days) can inhibit the viability of CHP-134 neuroblastoma cells, with an EC50 value of 88 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CHP-134 neuroblastoma tumor-bearing mouse xenograft model[1]
-
Dosage:30 mg/kg, 100 mg/kg
-
Administration:p.o., twice daily for 16 days
-
Result:Was well-tolerated with no significant body weight loss observed during the treatment period, and the final tumor growth inhibition rates were 115% (30 mg/kg group) and 117% (100 mg/kg group), respectively.
Chemical Information
-
Molecular Weight 503.40
-
Formula C20H19F6N7O2
-
SMILES
O=C(NC1=CNN=C1C2=CC3=C(C=N2)C=NN3CC(F)(F)F)N4C5(C[C@@](C(F)(F)F)(CC4)O)CC5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)